{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:55:20Z","timestamp":1771862120305,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100016209","name":"Bilimsel Ara\u015ft\u0131rma Projeleri, Erciyes \u00dcniversitesi","doi-asserted-by":"publisher","award":["TDK-2019-9670"],"award-info":[{"award-number":["TDK-2019-9670"]}],"id":[{"id":"10.13039\/501100016209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Neurobiol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s10571-022-01286-5","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T10:02:57Z","timestamp":1665482577000},"page":"2071-2087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Beneficial Clinical Effects of Teriflunomide in Experimental Autoimmune Myasthenia Gravis and the Investigation of the Possible Immunological Mechanisms"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-9949","authenticated-orcid":false,"given":"Emel","family":"Koseoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9860-4010","authenticated-orcid":false,"given":"Neslihan","family":"Sungur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-2620","authenticated-orcid":false,"given":"Sabahattin","family":"Muhtaroglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-1835","authenticated-orcid":false,"given":"Gokmen","family":"Zararsiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0721-6213","authenticated-orcid":false,"given":"Ahmet","family":"Eken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"1286_CR1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4049\/jimmunol.142.3.999","volume":"142","author":"I Amaldi","year":"1989","unstructured":"Amaldi I, Reith W, Berte C, Mach B (1989) Induction of HLA class II genes by IFN-gamma is transcriptional and requires a trans-acting protein. J Immunol 142:999\u20131004","journal-title":"J Immunol"},{"key":"1286_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","volume":"74","author":"A Bar-Or","year":"2014","unstructured":"Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H (2014) Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74:659\u2013674. https:\/\/doi.org\/10.1007\/s40265-014-0212-x","journal-title":"Drugs"},{"key":"1286_CR3","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.4049\/jimmunol.1300161","volume":"190","author":"A Bortnick","year":"2013","unstructured":"Bortnick A, Allman D (2013) What is and what should always have been: long-lived plasma cells induced by T cell-independent antigens. J Immunol 190:5913\u20135918. https:\/\/doi.org\/10.4049\/jimmunol.1300161","journal-title":"J Immunol"},{"key":"1286_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10:1\u20139. https:\/\/doi.org\/10.1186\/1471-2377-10-46","journal-title":"BMC Neurol"},{"key":"1286_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clim.2011.02.011","volume":"142","author":"MC Claussen","year":"2012","unstructured":"Claussen MC, Korn T (2012) Immune mechanisms of new therapeutic strategies in MS- Teriflunomide. Clin Immunol 142:49\u201356. https:\/\/doi.org\/10.1016\/j.clim.2011.02.011","journal-title":"Clin Immunol"},{"key":"1286_CR6","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2013) Assessment report AUBAGIO, International mon-proprietary name: TERIFLUNOMIDE Procedure No. EMEA\/H\/C\/002514\/0000. https:\/\/www.ema.europa.eu\/documents\/assessment-report\/aubagio-epar-public-assessment-report_en.pdf. Accessed 27 March 2022"},{"key":"1286_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, Group T.T. (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13:247\u2013256. https:\/\/doi.org\/10.1016\/S1474-4422(13)70308-9","journal-title":"Lancet Neurol"},{"issue":"5","key":"1286_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40265-018-0889-3","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S (2018) A review in generalized myasthenia gravis. Drugs 78(5):607. https:\/\/doi.org\/10.1007\/s40265-018-0889-3","journal-title":"Drugs"},{"key":"1286_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/281492a0","volume":"281","author":"PL Ey","year":"1979","unstructured":"Ey PL, Prowse SJ, Jenkin CR (1979) Complement-fixing IgG1 constitutes a new subclass of mouse IgG. Nature 281:492\u2013493. https:\/\/doi.org\/10.1038\/281492a0","journal-title":"Nature"},{"key":"1286_CR10","doi-asserted-by":"publisher","first-page":"e00776","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A, Nowak RJ, O\u2019Connor KC (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:e00776. https:\/\/doi.org\/10.3389\/fimmu.2020.00776","journal-title":"Front Immunol"},{"key":"1286_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ejcts\/ezs663","volume":"44","author":"PL Filosso","year":"2013","unstructured":"Filosso PL, Galassi C, Ruffini E, Margaritora S, Bertolaccini L, Casadio C, Anile M, Venuta F (2013) Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study. Eur J Cardiothorac Surg 44:219\u2013224. https:\/\/doi.org\/10.1093\/ejcts\/ezs663 (discussion 224)","journal-title":"Eur J Cardiothorac Surg"},{"key":"1286_CR12","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1212\/NXI.0000000000000403","volume":"4","author":"I Gandoglia","year":"2017","unstructured":"Gandoglia I, Ivaldi F, Laroni A, Benvenuto F, Solaro C, Mancardi G, Kerlero de Rosbo N, Uccelli A (2017) Teriflunomide treatment reduces B cells in patients with MS. Neurol Neuroimmunol Neuroinflamm 4:e403. https:\/\/doi.org\/10.1212\/NXI.0000000000000403","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1286_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69:418\u2013422. https:\/\/doi.org\/10.1002\/ana.22312","journal-title":"Ann Neurol"},{"key":"1286_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368. https:\/\/doi.org\/10.1038\/85520","journal-title":"Nat Med"},{"key":"1286_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr (2018) Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci 1412:113\u2013128. https:\/\/doi.org\/10.1111\/nyas.13522","journal-title":"Ann N Y Acad Sci"},{"key":"1286_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fimmu.2019.00721","volume":"10","author":"L Khodadadi","year":"2019","unstructured":"Khodadadi L, Cheng QY, Radbruch A, Hiepe F (2019) The maintenance of memory plasma cells. Front Immunol 10:721. https:\/\/doi.org\/10.3389\/fimmu.2019.00721","journal-title":"Front Immunol"},{"key":"1286_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0165-5728(81)90015-1","volume":"1","author":"AK Lefvert","year":"1981","unstructured":"Lefvert AK, Cuenoud S, Fulpius BW (1981) Binding-properties and subclass distribution of anti-acetylcholine Receptor antibodies in myasthenia-gravis. J Neuroimmunol 1:125\u2013135. https:\/\/doi.org\/10.1016\/0165-5728(81)90015-1","journal-title":"J Neuroimmunol"},{"key":"1286_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jneuroim.2013.10.003","volume":"265","author":"L Li","year":"2013","unstructured":"Li L, Liu JC, Delohery T, Zhang DH, Arendt C, Jones C (2013) The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol 265:82\u201390. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.10.003","journal-title":"J Neuroimmunol"},{"key":"1286_CR19","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1081\/NCN-200027547","volume":"23","author":"M Loffler","year":"2004","unstructured":"Loffler M, Klein A, Hayek-Ouassini M, Knecht W, Konrad L (2004) Dihydroorotate dehydrogenase mRNA and protein expression analysis in normal and drug-resistant cells. Nucleosides Nucleotides Nucleic Acids 23:1281\u20131285. https:\/\/doi.org\/10.1081\/NCN-200027547","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1286_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJGM.S88552","volume":"9","author":"R Mantegazza","year":"2016","unstructured":"Mantegazza R, Cordiglieri C, Consonni A, Baggi F (2016) Animal models of myasthenia gravis: utility and limitations. Int J Gen Med 9:53\u201364. https:\/\/doi.org\/10.2147\/IJGM.S88552","journal-title":"Int J Gen Med"},{"key":"1286_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.20061","volume":"55","author":"J McConville","year":"2004","unstructured":"McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55:580\u2013584. https:\/\/doi.org\/10.1002\/ana.20061","journal-title":"Ann Neurol"},{"key":"1286_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fimmu.2014.00065","volume":"5","author":"L Moens","year":"2014","unstructured":"Moens L, Tangye SG (2014) Cytokine-mediated regulation of plasma cell generation: IL-21 takes center stage. Front Immunol 5:65. https:\/\/doi.org\/10.3389\/fimmu.2014.00065","journal-title":"Front Immunol"},{"key":"1286_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nri3795","volume":"15","author":"SL Nutt","year":"2015","unstructured":"Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM (2015) The generation of antibody-secreting plasma cells. Nat Rev Immunol 15:160\u2013171. https:\/\/doi.org\/10.1038\/nri3795","journal-title":"Nat Rev Immunol"},{"key":"1286_CR24","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O'Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293\u20131303. https:\/\/doi.org\/10.1056\/NEJMoa1014656","journal-title":"N Engl J Med"},{"key":"1286_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1126\/scitranslmed.aao5563","volume":"18","author":"V Posevitz","year":"2012","unstructured":"Posevitz V, Chudyka D, Kurth F, Wiendl H (2012) Teriflunomide suppresses antigen induced T-cell expansion in a TCR avidity dependent fashion. Mult Scler J 18:519\u2013519. https:\/\/doi.org\/10.1126\/scitranslmed.aao5563","journal-title":"Mult Scler J"},{"key":"1286_CR26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/sj.leu.2404922","volume":"22","author":"I Ringshausen","year":"2008","unstructured":"Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T (2008) The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia 22:635\u2013638. https:\/\/doi.org\/10.1038\/sj.leu.2404922","journal-title":"Leukemia"},{"key":"1286_CR27","first-page":"82","volume":"67","author":"A Rodgaard","year":"1987","unstructured":"Rodgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S (1987) Acetylcholine-Receptor Antibody in Myasthenia-Gravis\u2014Predominance of Igg Subclass-1 and Subclass-3. Clin Exp Immunol 67:82\u201388","journal-title":"Clin Exp Immunol"},{"key":"1286_CR28","doi-asserted-by":"publisher","first-page":"21682","DOI":"10.1074\/jbc.273.34.21682","volume":"273","author":"K Ruckemann","year":"1998","unstructured":"Ruckemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, Simmonds HA (1998) Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 273:21682\u201321691. https:\/\/doi.org\/10.1074\/jbc.273.34.21682","journal-title":"J Biol Chem"},{"issue":"Suppl 7","key":"1286_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/clim.1999.4807","volume":"73","author":"K Shigemoto","year":"2015","unstructured":"Shigemoto K, Takashima R, Motohashi N, Mori S (2015) Animal models of myasthenia gravis. Nihon Rinsho 73(Suppl 7):97\u2013104. https:\/\/doi.org\/10.1006\/clim.1999.4807","journal-title":"Nihon Rinsho"},{"key":"1286_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00007890-199602270-00020","volume":"61","author":"K Siemasko","year":"1996","unstructured":"Siemasko K, Chong AS-F, Williams JW, Bremer EG, Finnegan A (1996) Regulation of B cell function by the immunosupressive agent leflunomide. Transplantation 61:635\u2013642. https:\/\/doi.org\/10.1097\/00007890-199602270-00020","journal-title":"Transplantation"},{"key":"1286_CR31","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.4049\/jimmunol.160.4.1581","volume":"160","author":"K Siemasko","year":"1998","unstructured":"Siemasko K, Chong AS-F, Jack HM, Gong H, Williams JW, Finnegan A (1998) Inhibition oj JAK3 and STAT6 tyrosine phosphorylation by the immunosupressive drug leflunomide leads to a block in IgG1 production. J Immunol 160:1581\u20131588","journal-title":"J Immunol"},{"key":"1286_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI (2014) Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis 15:167\u2013178. https:\/\/doi.org\/10.1097\/CND.0000000000000034","journal-title":"J Clin Neuromuscul Dis"},{"key":"1286_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jocn.2016.11.003","volume":"38","author":"KK Sonkar","year":"2017","unstructured":"Sonkar KK, Bhoi SK, Dubey D, Kalita J, Misra UK (2017) Direct and indirect cost of myasthenia gravis: a prospective study from a tertiary care teaching hospital in India. J Clin Neurosci 38:114\u2013117. https:\/\/doi.org\/10.1016\/j.jocn.2016.11.003","journal-title":"J Clin Neurosci"},{"key":"1286_CR34","doi-asserted-by":"publisher","first-page":"94263","DOI":"10.1172\/jci.insight.94263","volume":"2","author":"P Stathopoulos","year":"2017","unstructured":"Stathopoulos P, Kumar A, Nowak RJ, O\u2019Connor KC (2017) Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight 2:94263. https:\/\/doi.org\/10.1172\/jci.insight.94263","journal-title":"JCI Insight"},{"key":"1286_CR35","doi-asserted-by":"publisher","first-page":"730342","DOI":"10.3389\/fimmu.2021.730342","volume":"12","author":"G Tilly","year":"2021","unstructured":"Tilly G, Cadoux M, Garcia A, Morille J, Wiertlewski S, Pecqueur C, Brouard S, Laplaud D, Degauque N (2021) Teriflunomide treatment of multiple sclerosis selectively modulates CD8 memory T cells. Front Immunol 12:730342. https:\/\/doi.org\/10.3389\/fimmu.2021.730342","journal-title":"Front Immunol"},{"key":"1286_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.expneurol.2015.02.009","volume":"270","author":"E Tuzun","year":"2015","unstructured":"Tuzun E, Berrih-Aknin S, Brenner T, Kusner LL, Le Panse R, Yang H, Tzartos S, Christadoss P (2015) Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization. Exp Neurol 270:11\u201317. https:\/\/doi.org\/10.1016\/j.expneurol.2015.02.009","journal-title":"Exp Neurol"},{"key":"1286_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1080\/08820139.2017.1299754","volume":"46","author":"C Ulusoy","year":"2017","unstructured":"Ulusoy C, Cavus F, Yilmaz V, Tuzun E (2017) Immunization with recombinantly expressed LRP4 induces experimental autoimmune myasthenia gravis in C57BL\/6 mice. Immunol Invest 46:490\u2013499. https:\/\/doi.org\/10.1080\/08820139.2017.1299754","journal-title":"Immunol Invest"},{"issue":"3","key":"1286_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, Yasuda M, Nagane Y, Utsugisawa K (2021) Roles ofcytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol 203(3):366\u2013374. https:\/\/doi.org\/10.1111\/cei.13546","journal-title":"Clin Exp Immunol"},{"key":"1286_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","volume":"2","author":"A Vincent","year":"2002","unstructured":"Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797\u2013804","journal-title":"Nat Rev Immunol"},{"key":"1286_CR40","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/nri916","volume":"8","author":"Z Wang","year":"2017","unstructured":"Wang Z, Yan YP (2017) Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica. Front Immunol 8:1785. https:\/\/doi.org\/10.1038\/nri916","journal-title":"Front Immunol"},{"key":"1286_CR41","unstructured":"Wiendl H, Seze JD, Cross AH, Winthrop K, Gupta AD, Kerloeguen C, Pingili R, Sullivam R, Ramanathan K, Kappos L (2020) Serum immunoglobulin levels and infections in relapsing multiple sclerosis. https:\/\/www.charcot-ms.org\/28th-annual-meeting-digital\/poster-presentations\/clinical\/heinz-wiendl-33"},{"key":"1286_CR42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/08820139.2020.1785491","volume":"50","author":"V Yilmaz","year":"2021","unstructured":"Yilmaz V, Ulusoy C, Hajtovic S, Turkoglu R, Kurtuncu M, Tzartos J, Lazaridis K, Tuzun E (2021) Effects of Teriflunomide on B cell subsets in MuSK-induced experimental autoimmune myasthenia gravis and multiple sclerosis. Immunol Invest 50:671\u2013684. https:\/\/doi.org\/10.1080\/08820139.2020.1785491","journal-title":"Immunol Invest"},{"key":"1286_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1084\/jem.184.2.349","volume":"184","author":"GX Zhang","year":"1996","unstructured":"Zhang GX, Xiao BG, Bakhiet M, van der Meide P, Wigzell H, Link H, Olsson T (1996) Both CD4(+) and CD8(+) T cells are essential to induce experimental autoimmune myasthenia gravis. J Exp Med 184:349\u2013356. https:\/\/doi.org\/10.1084\/jem.184.2.349","journal-title":"J Exp Med"},{"key":"1286_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Cuvelier MF, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139\u2013145. https:\/\/doi.org\/10.1016\/j.jaut.2013.12.004","journal-title":"J Autoimmun"}],"container-title":["Cellular and Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-022-01286-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10571-022-01286-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-022-01286-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T06:29:46Z","timestamp":1687501786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10571-022-01286-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1007\/s10571-022-01286-5","relation":{},"ISSN":["0272-4340","1573-6830"],"issn-type":[{"value":"0272-4340","type":"print"},{"value":"1573-6830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"30 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}